Goldman Sachs’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$5.83B Buy
6,340,865
+390,971
+7% +$396M 0.67% 15
2025
Q4
$6.39B Sell
5,949,894
-704,912
-11% -$674M 0.78% 14
2025
Q3
$5.08B Buy
6,654,806
+1,153,495
+21% +$858M 0.62% 21
2025
Q2
$4.29B Buy
5,501,311
+168,018
+3% +$131M 0.58% 24
2025
Q1
$4.4B Buy
5,333,293
+369,603
+7% +$308M 0.71% 18
2024
Q4
$3.83B Buy
4,963,690
+313,240
+7% +$259M 0.6% 21
2024
Q3
$4.12B Sell
4,650,450
-277,490
-6% -$249M 0.66% 18
2024
Q2
$4.46B Buy
4,927,940
+408,381
+9% +$327M 0.75% 16
2024
Q1
$3.52B Sell
4,519,559
-160,374
-3% -$114M 0.62% 17
2023
Q4
$2.73B Sell
4,679,933
-159,123
-3% -$92.9M 0.5% 25
2023
Q3
$2.6B Sell
4,839,056
-716
-0% -$369K 0.55% 24
2023
Q2
$2.27B Sell
4,839,772
-845,234
-15% -$354M 0.49% 30
2023
Q1
$1.95B Buy
5,685,006
+847,845
+18% +$286M 0.45% 29
2022
Q4
$1.77B Buy
4,837,161
+70,963
+1% +$25.2M 0.43% 28
2022
Q3
$1.54B Buy
4,766,198
+91,654
+2% +$29M 0.39% 32
2022
Q2
$1.52B Buy
4,674,544
+180,850
+4% +$54.3M 0.38% 36
2022
Q1
$1.29B Buy
4,493,694
+208,962
+5% +$53.8M 0.27% 47
2021
Q4
$1.18B Sell
4,284,732
-471,398
-10% -$120M 0.24% 58
2021
Q3
$1.1B Buy
4,756,130
+460,649
+11% +$114M 0.23% 53
2021
Q2
$986M Buy
4,295,481
+7,172
+0.2% +$1.44M 0.22% 63
2021
Q1
$801M Buy
4,288,309
+247,977
+6% +$48.5M 0.2% 73
2020
Q4
$682M Buy
4,040,332
+463,355
+13% +$69.2M 0.18% 96
2020
Q3
$529M Sell
3,576,977
-721,527
-17% -$112M 0.15% 119
2020
Q2
$706M Sell
4,298,504
-514,552
-11% -$79M 0.21% 75
2020
Q1
$668M Sell
4,813,056
-838,299
-15% -$115M 0.24% 80
2019
Q4
$743M Buy
5,651,355
+503,864
+10% +$58.4M 0.19% 93
2019
Q3
$576M Sell
5,147,491
-1,358,855
-21% -$151M 0.17% 104
2019
Q2
$721M Buy
6,506,346
+936,531
+17% +$110M 0.21% 78
2019
Q1
$723M Sell
5,569,815
-1,355,606
-20% -$165M 0.22% 79
2018
Q4
$801M Sell
6,925,421
-526,608
-7% -$58.8M 0.26% 61
2018
Q3
$800M Buy
7,452,029
+24,631
+0.3% +$2.46M 0.21% 78
2018
Q2
$634M Sell
7,427,398
-1,666,910
-18% -$137M 0.17% 95
2018
Q1
$704M Buy
9,094,308
+386,842
+4% +$31.1M 0.18% 95
2017
Q4
$735M Buy
8,707,466
+1,023,196
+13% +$87.1M 0.18% 93
2017
Q3
$657M Sell
7,684,270
-363,888
-5% -$29.8M 0.16% 97
2017
Q2
$662M Buy
8,048,158
+632,972
+9% +$51.6M 0.17% 94
2017
Q1
$624M Sell
7,415,186
-170,330
-2% -$13.6M 0.17% 98
2016
Q4
$558M Buy
7,585,516
+1,513,504
+25% +$113M 0.16% 101
2016
Q3
$487M Sell
6,072,012
-858,417
-12% -$68.7M 0.15% 103
2016
Q2
$546M Buy
6,930,429
+3,969,317
+134% +$299M 0.18% 83
2016
Q1
$213M Sell
2,961,112
-702,879
-19% -$53.2M 0.07% 315
2015
Q4
$309M Buy
3,663,991
+745,676
+26% +$61.9M 0.1% 214
2015
Q3
$244M Sell
2,918,315
-1,119,227
-28% -$94.5M 0.08% 245
2015
Q2
$337M Sell
4,037,542
-950,060
-19% -$72.4M 0.1% 193
2015
Q1
$362M Sell
4,987,602
-100,144
-2% -$7.13M 0.12% 173
2014
Q4
$351M Buy
5,087,746
+154,899
+3% +$10.5M 0.11% 179
2014
Q3
$320M Sell
4,932,847
-898,729
-15% -$56.9M 0.1% 194
2014
Q2
$363M Sell
5,831,576
-1,385,389
-19% -$82.7M 0.11% 171
2014
Q1
$425M Buy
7,216,965
+321,868
+5% +$18M 0.14% 134
2013
Q4
$352M Buy
6,895,097
+689,846
+11% +$34.5M 0.12% 171
2013
Q3
$312M Buy
6,205,251
+359,084
+6% +$18.8M 0.12% 169
2013
Q2
$287M Buy
+5,846,167
New +$318M 0.11% 174

Other funds holding LLY

Goldman Sachs's LLY Position: Q1 2026 in Review

Goldman Sachs increased its Eli Lilly (LLY) stake by 6.6% in Q1 2026, buying an estimated $396M and bringing the position to 6,340,865 shares worth $5.83B. The position accounts for 0.67% of the portfolio, ranked #15.

Goldman Sachs first reported a position in LLY in Q2 2013 and has held it in 52 quarters since. The position peaked at $6.39B in Q4 2025. 4,353 funds tracked by Wall St. Rank hold LLY as of Q1 2026.

  • Goldman Sachs held 6,340,865 shares of Eli Lilly worth $5.83B as of Q1 2026.
  • Goldman Sachs bought 390,971 Eli Lilly shares in Q1 2026, an estimated $396M.
  • Eli Lilly made up 0.67% of Goldman Sachs's portfolio in Q1 2026, its #15 holding.
  • Goldman Sachs first reported a position in Eli Lilly in Q2 2013 and has held it in 52 quarters since.
  • Goldman Sachs's Eli Lilly position peaked at $6.39B in Q4 2025.
  • 4,353 funds tracked by Wall St. Rank held Eli Lilly as of Q1 2026.

Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.